***original publicationdate 30-7-2020, but because of recent developments republished***
Robin Veenman (former research intern at Wemos and Pharmaceutical Accountability Foundation & master student Political Science at the University of Amsterdam):
“Earlier this year, the Association Innovative Medicines (or Vereniging Innovatieve Geneesmiddelen – VIG – the industry association for the Dutch branches of innovative pharmaceutical companies) published its new code of conduct. Unfortunately, in a time when high medicine prices are a pressing societal problem, the code omits any mentioning of the pharmaceutical industry’s pricing policy.”
“For my research at Wemos and Pharmaceutical Accountability Foundation, I aimed to find out why, and came to the conclusion that the code is a symptom of a neoliberal system within the pharmaceutical industry, guided by profit maximisation instead of public health.”
Read the thesis here.